Visual outcomes, efficacy, and surgical complications associated with intracameral phenylephrine 1.0%/ketorolac 0.3% administered during cataract surgery

Figures & data

Table 1 Characteristics of eligible patients

Surgeon	Treatment	N	Mean age, years (SD)	Female, %	Eye, % right	Femtosecond laser, %	α-blocker, %
Overall	P/K	260	75.5 (7.2)	71.5	50.4	47.3	8.1
	Epi	381	67.4 (10.7)	59.6	51.2	40.7	8.4
	p-value		<0.0001	0.0016	0.8433	0.0980	0.8843
EDD	P/K	141	74.7 (7.1)	68.8	50.4	52.5	6.4
	Epi	169	63.5 (10.8)	55.6	49.7	54.4	5.9
	p-value		<0.0001	0.0168	0.9096	0.7321	0.8658
JB	P/K	32	77.6 (6.3)	87.5	53.1	21.9	6.3
	Epi	59	71.3 (9.5)	74.6	50.8	16.9	10.2
	p-value		0.0003	0.1210	0.8382	0.5825	0.5075
GD	P/K	28	75.5 (7.6)	82.1	46.4	39.3	7.1
	Epi	79	69.7 (10.9)	72.2	50.6	36.7	8.9
	p-value		0.0027	0.2691	0.7076	0.8136	0.7724
RJL	P/K	59	76.8 (7.3)	64.4	50.8	52.5	13.6
	Epi	74	70.8 (8.2)	43.2	52.7	32.4	12.2
	p-value		<0.0001	0.0147	0.8332	0.0202	0.8133
Comparison across surgeons	P/K	260	0.0451	0.0564	0.9644	0.0107	0.3924
	Epi	381	<0.0001	0.0002	0.9798	<0.0001	0.4003

Abbreviations: Epi, epinephrine; P/K, phenylephrine/ketorolac; SD, standard deviation.

Figure 1 (A) Frequency distribution and average LOS in the study population. (B) LOS by all four surgeons (EDD, GD, JB, and RJL). (C) Correlation between patient age and LOS. (D) The average LOS in different age groups in P/K and Epi groups. (E) The average LOS by each surgeon in femtosecond laser and manual cataract surgery.

Abbreviations: Epi, epinephrine; P/K, phenylephrine/ketorolac; LOS, length of stay.

Figure 2 (A) Complication rate in eyes with or without mydriatic-assist device use. (B) Complication rate in P/K and Epi groups. (C) Complication rate with or without mydriatic-assist device use in P/K and Epi groups.

Abbreviations: Epi, epinephrine; P/K, phenylephrine/ketorolac.

Figure 3 (A) Mydriatic-assist device rate in eyes that underwent femtosecond laser-assisted cataract surgery and manual surgery. (B) Mydriatic-assist device rate by each surgeon in P/K and Epi groups. (C) Mydriatic-assist device rate in patients with or without history of α₁ antagonist use in P/K and Epi groups.

Abbreviations: Epi, epinephrine; P/K, phenylephrine/ketorolac.

Figure 4 (A) UCVA at POD 1 and BCVA at POM 1 in P/K and Epi groups. (B) POD 1 UCVA in different age groups in P/K and Epi groups.

Abbreviations: BCVA, best-corrected visual acuity; Epi, epinephrine; P/K, phenylephrine/ketorolac; POD 1, postoperative day 1; POM 1, postoperative month 1; UCVA, uncorrected visual acuity.